81 related articles for article (PubMed ID: 16511743)
1. [Positron emission tomography (PET) in oncology: a part of medical therapeutic expertise].
Bamberg M; Diehl V; Herrmann T; Jürgens H; Siewert JR; Kotzerke J;
Dtsch Med Wochenschr; 2006 Mar; 131(10):512-5. PubMed ID: 16511743
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
[TBL] [Abstract][Full Text] [Related]
3. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
4. [Positron emission tomography (PET)--current state of the art and future perspectives].
von Schulthess GK;
Praxis (Bern 1994); 2005 Aug; 94(35):1331-7. PubMed ID: 16171004
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
[TBL] [Abstract][Full Text] [Related]
6. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
7. Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning.
Weber WA; Grosu AL; Czernin J
Nat Clin Pract Oncol; 2008 Mar; 5(3):160-70. PubMed ID: 18253106
[TBL] [Abstract][Full Text] [Related]
8. [Positron-emission tomography (PET) and PET/CT in head and neck cancer - recommendations of an interdisciplinary consensus conference].
Kohlfürst S; Markitz M; Raunik W; Eckel HE; Kresnik E; Hausegger K; Salzwimmer M; Gaggl A; Chiari F; Lind P
Laryngorhinootologie; 2009 Feb; 88(2):84-90. PubMed ID: 19219754
[TBL] [Abstract][Full Text] [Related]
9. [Reimbursement of the PET in oncology in Europe: a questionnaire based survey].
Dietlein M; Schicha H
Nuklearmedizin; 2003 Jun; 42(3):80-5. PubMed ID: 12802468
[TBL] [Abstract][Full Text] [Related]
10. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
Lejeune C; Bismuth MJ; Conroy T; Zanni C; Bey P; Bedenne L; Faivre J; Arveux P; Guillemin F
J Nucl Med; 2005 Dec; 46(12):2020-8. PubMed ID: 16330566
[TBL] [Abstract][Full Text] [Related]
11. Integrated PET/CT and cancer imaging.
De Wever W; Coolen J; Verschakelen JA
JBR-BTR; 2009; 92(1):13-9. PubMed ID: 19358480
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer.
Kurien G; Hu J; Harris J; Seikaly H
J Otolaryngol Head Neck Surg; 2011 Dec; 40(6):468-72. PubMed ID: 22420434
[TBL] [Abstract][Full Text] [Related]
13. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Schirmerreschaft der Deutschen Gesellschaft for Nuklearmedizin].
Reske SN; Bares R; Büll U; Guhlmann A; Moser E; Wannenmacher MF
Nuklearmedizin; 1996 Apr; 35(2):42-52. PubMed ID: 8721575
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of PET-CT : product safety, clinical usefulness, reimbursement in Germany and the USA].
Biersack HJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):594-600. PubMed ID: 19399376
[TBL] [Abstract][Full Text] [Related]
16. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
17. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
[TBL] [Abstract][Full Text] [Related]
18. The role of PET in monitoring therapy.
Hicks RJ
Cancer Imaging; 2005 Jun; 5(1):51-7. PubMed ID: 16154820
[TBL] [Abstract][Full Text] [Related]
19. [The value of positron emission tomography in the diagnosis and treatment of oesophageal cancer].
Omloo JM; Westerterp M; Sloof GW; Hoekstra OS; van Lanschot JJ
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):365-70. PubMed ID: 18380382
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
